STRIDER: A phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts with KRAS G12C+ NSCLC and bRain metastases

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505721-13-00

Acronym

CJDQ443B1NL01T

Enrollment

Registered

2023-11-20

Start date

Unknown

Completion date

2024-06-10

Last updated

2023-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with KRAS G12C+ non small cell lung cancer and brain metastases

Brief summary

Brain Metastases Objective Response Rate (RANO-BM criteria)

Detailed description

There are two secondary key endpoints: brain metastase disease control rate (RANO-BM) AND median CNS progression-free survival (RANO-BM)., Extracranial objective response rate (ORR) and disease control rate (DCR) (RECIST 1.1), Median extracranial progression-free survival (PFS) (based on RECIST 1.1), Median overall PFS (based on RANO-BM for BM and RECIST 1.1 for extracranial lesions), Median overall survival (OS), Quality of life (EORTC QLQ-BN20 and EORTC QLQ-C30), Safety (CTCAE v5.0)

Interventions

DRUGJDQ443

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Brain Metastases Objective Response Rate (RANO-BM criteria)	—

Secondary

Measure	Time frame
There are two secondary key endpoints: brain metastase disease control rate (RANO-BM) AND median CNS progression-free survival (RANO-BM)., Extracranial objective response rate (ORR) and disease control rate (DCR) (RECIST 1.1), Median extracranial progression-free survival (PFS) (based on RECIST 1.1), Median overall PFS (based on RANO-BM for BM and RECIST 1.1 for extracranial lesions), Median overall survival (OS), Quality of life (EORTC QLQ-BN20 and EORTC QLQ-C30), Safety (CTCAE v5.0)	—

Measure

Time frame

—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026